If you or a loved one has been diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, you may be wondering about the various treatment ...

CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis. This is an ASCO Meeting ...

We report the antimicrobial susceptibility patterns of the most frequently isolated Gram-positive bacteria in the Brazilian hospitals ... bacteriostatic and has not been recommended for the treatment ...

There is limited evidence on the dermoscopy of cutaneous metastases from breast cancer. 5-7 In our case, we report findings consistent with the literature with the presence of branching linear or ...

Tempest Therapeutics, Inc. recently presented new data at the 2025 AACR Annual Meeting highlighting the potential of its drug amezalpat as a novel cancer treatment, demonstrating its ability to ...

Anacor Pharmaceuticals, Inc., 1060 East Meadow Circle, Palo Alto, California 94303, Galileo Pharmaceuticals, Inc., 5301 Patrick Henry, Drive Santa Clara, California ...

Introduction: Carbapenem-resistant (CR) Gram-negative pathogens are classified by the WHO ... with a minimal lethal dose of bacteria (1*10 8), then randomly divided into a treatment group and a ...

Introduction: Anaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, ...

Philippe Martin, Viatris’s Chief R&D Officer, highlighted the potential for MR-107A-02 to become a first-line treatment for acute pain without the risks associated with opioids.

PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of ...

The most encouraging aspect of this Phase II study is AK3280's positive signal in pulmonary function improvement ... and we look forward to seeing this innovation to become a global standard treatment ...